Cargando…

Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy

BACKGROUND: Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoa...

Descripción completa

Detalles Bibliográficos
Autores principales: Depypere, Lieven, Thomas, Melissa, Moons, Johnny, Coosemans, Willy, Lerut, Toni, Prenen, Hans, Haustermans, Karin, Van Veer, Hans, Nafteux, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537364/
https://www.ncbi.nlm.nih.gov/pubmed/31133018
http://dx.doi.org/10.1186/s12957-019-1630-8
_version_ 1783421989884526592
author Depypere, Lieven
Thomas, Melissa
Moons, Johnny
Coosemans, Willy
Lerut, Toni
Prenen, Hans
Haustermans, Karin
Van Veer, Hans
Nafteux, Philippe
author_facet Depypere, Lieven
Thomas, Melissa
Moons, Johnny
Coosemans, Willy
Lerut, Toni
Prenen, Hans
Haustermans, Karin
Van Veer, Hans
Nafteux, Philippe
author_sort Depypere, Lieven
collection PubMed
description BACKGROUND: Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection. METHODS: We retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002–2010 versus 2011–2015) and histology (adenocarcinoma versus squamous cell carcinoma). RESULTS: In 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients’ own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients’ refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months. CONCLUSIONS: One in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons.
format Online
Article
Text
id pubmed-6537364
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65373642019-05-30 Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy Depypere, Lieven Thomas, Melissa Moons, Johnny Coosemans, Willy Lerut, Toni Prenen, Hans Haustermans, Karin Van Veer, Hans Nafteux, Philippe World J Surg Oncol Research BACKGROUND: Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection. METHODS: We retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002–2010 versus 2011–2015) and histology (adenocarcinoma versus squamous cell carcinoma). RESULTS: In 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients’ own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients’ refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months. CONCLUSIONS: One in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons. BioMed Central 2019-05-27 /pmc/articles/PMC6537364/ /pubmed/31133018 http://dx.doi.org/10.1186/s12957-019-1630-8 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Depypere, Lieven
Thomas, Melissa
Moons, Johnny
Coosemans, Willy
Lerut, Toni
Prenen, Hans
Haustermans, Karin
Van Veer, Hans
Nafteux, Philippe
Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
title Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
title_full Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
title_fullStr Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
title_full_unstemmed Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
title_short Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
title_sort analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537364/
https://www.ncbi.nlm.nih.gov/pubmed/31133018
http://dx.doi.org/10.1186/s12957-019-1630-8
work_keys_str_mv AT depyperelieven analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT thomasmelissa analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT moonsjohnny analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT coosemanswilly analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT leruttoni analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT prenenhans analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT haustermanskarin analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT vanveerhans analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy
AT nafteuxphilippe analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy